Huang, Huang http://orcid.org/0000-0002-3944-5635
Howard, Christina A.
Zari, Sergei
Cho, Hyo Je
Shukla, Shirish
Li, Hao
Ndoj, Juliano
González-Alonso, Paula http://orcid.org/0000-0002-5343-8300
Nikolaidis, Caroline
Abbott, Joshua http://orcid.org/0000-0002-1897-3228
Rogawski, David S.
Potopnyk, Mykhaylo A. http://orcid.org/0000-0002-4543-2785
Kempinska, Katarzyna
Miao, Hongzhi
Purohit, Trupta
Henderson, Andrew
Mapp, Anna http://orcid.org/0000-0003-0791-8327
Sulis, Maria Luisa
Ferrando, Adolfo
Grembecka, Jolanta
Cierpicki, Tomasz http://orcid.org/0000-0003-2058-0658
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35 CA210065)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA160467, CA229250, CA226759, CA207272)
Leukemia and Lymphoma Society (6485-16, 6579-20, 6111-14, 6564-19, 1340-17)
Article History
Received: 30 August 2019
Accepted: 29 June 2020
First Online: 31 August 2020
Competing interests
: H.H., C.A.H., S.Z., H.J.C., M.A.P., J.G. and T.C. are coinventors on a patent application for NSD1 inhibitors. T.C. and J.G. received prior support from Kura Oncology for an unrelated project and received licensing royalties from Kura Oncology. A.F. is consulting for Ayala Pharmaceuticals and SpringWorks Therapeutics; he received previous research support from Pfizer, Bristol Myers Squibb, Merck and Eli Lilly, as well as patent and reagent licensing royalties from Novartis, EMD Millipore and Applied Biological Materials.